Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $20.00.

A number of equities analysts have commented on the stock. JMP Securities reissued a “market outperform” rating and issued a $22.00 price objective on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 9th. JPMorgan Chase & Co. reduced their price objective on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 6th. Evercore ISI raised Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research report on Thursday, October 10th.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA opened at $10.66 on Wednesday. The stock has a 50 day moving average price of $11.51 and a 200-day moving average price of $12.63. Enanta Pharmaceuticals has a one year low of $8.11 and a one year high of $17.80. The company has a market capitalization of $225.89 million, a P/E ratio of -1.99 and a beta of 0.56.

Institutional Trading of Enanta Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new position in shares of Enanta Pharmaceuticals in the 2nd quarter worth $35,000. US Bancorp DE boosted its holdings in shares of Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 4,243 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new position in shares of Enanta Pharmaceuticals during the 1st quarter worth approximately $118,000. Virtu Financial LLC acquired a new stake in Enanta Pharmaceuticals in the first quarter valued at approximately $191,000. Finally, Quest Partners LLC grew its holdings in Enanta Pharmaceuticals by 511.2% in the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 9,692 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.